Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

BACKGROUND: The angiopoietin/Tie2 pathway is an attractive target for cancer therapy due to its well-known role in regulating angiogenesis. Trebananib, a recombinant peptide-Fc fusion protein, or peptibody, that binds to angiopoietin-1 (Ang1) and Ang2 to block their interaction with the Tie2 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Grenga, Italia, Kwilas, Anna R., Donahue, Renee N., Farsaci, Benedetto, Hodge, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647578/
https://www.ncbi.nlm.nih.gov/pubmed/26579226
http://dx.doi.org/10.1186/s40425-015-0096-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647578/
https://www.ncbi.nlm.nih.gov/pubmed/26579226
http://dx.doi.org/10.1186/s40425-015-0096-7

Ejemplares similares